课题基金 / 基金详情

Development of a TLR5 antagonist as a novel anti-inflammatory therapy for cystic fibrosis

Development of a TLR5 antagonist as a novel anti-inflammatory therapy for cystic fibrosis
开发 TLR5 拮抗剂作为囊性纤维化的新型抗炎疗法
批准号:
188108
负责人:
Turvey Stuart E
金额:
$10.93万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2009
资助国家:
加拿大
项目状态:
已结题
起止时间:
2009-04-01 至 2010-04-01

项目摘要

项目成果

Turvey Stuart E的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Cystic fibrosis (CF) is the most common, deadly genetic disease affecting young Canadians. Even today, only half of the people living with CF will survive beyond their mid-30's. New treatments for CF are critically needed. Lung disease is the major caus
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Harnessing early life developmental trajectories and the gut microbiota to identify new ways to prevent asthma and obesity.
  • 批准号:
    472653
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2022
  • 负责人:
    Turvey Stuart E
  • 依托单位:
Understanding Human Primary Atopic Disorders
  • 批准号:
    443565
  • 项目类别:
    Operating Grants
  • 资助金额:
    $55.73万
  • 财政年份:
    2021
  • 负责人:
    Turvey Stuart E
  • 依托单位:
Understanding Human Primary Atopic Disorders
  • 批准号:
    431803
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2020
  • 负责人:
    Turvey Stuart E
  • 依托单位:
Canada Research Chair Tier 1
  • 批准号:
    392587
  • 项目类别:
  • 资助金额:
    $101.99万
  • 财政年份:
    2018
  • 负责人:
    Turvey Stuart E
  • 依托单位:
海外基金